Figure 5: Dinaciclib but not JQ1 synergizes with ABT-263 to kill SCLC cells.
From: Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
(a) The indicated SCLC cell lines were treated with vehicle, 1 μM JQ1, or dinaciclib (10 nM for H196 and H82, or 20 nM for SW1271 and DMS114) in the absence or presence of 1 μM ABT-263 for 24 h. Cell death was quantified by annexin-V staining (mean±s.d., n=3). (b) A summary of EC50s of dinaciclib and JQ1 in SCLC cell lines. The indicated SCLC cell lines were untreated or treated with increasing concentrations of dinaciclib or JQ1. Cell viability was assessed by CellTiter-Glo assays at 72 h. (c) The expression of c-MYC in the indicated SCLC cell lines was assessed by an anti-c-Myc immunoblot. (d) The indicated SCLC cell lines were treated with vehicle, 1 μM JQ1, or 20 nM dinaciclib for 24 h. Cell death was quantified by annexin-V staining (mean±s.d., n=3). (e) H82, H2171, and H446 cells, treated with vehicle, 20 nM dinaciclib, or 1 μM JQ1 for 3 h, were assessed by qRT-PCR. Data were normalized against β-actin (mean±s.d., n=2 independent experiments). H82, H2171, and H446 cells, treated with vehicle, dinaciclib, or JQ1 for 24 h, were assessed by immunoblot analysis using the indicated antibodies. Unprocessed original scans of blots are shown in Supplementary Fig. 11.
